Compare Amgen, Inc. (AMGN) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Jumia Technologies AG - ADR — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Jumia Technologies AG - ADR trades at $6.94 (market cap $868.21M). The key difference: Amgen, Inc. is far larger — about 225.9× Jumia Technologies AG - ADR's market cap, and Amgen, Inc. pays a 2.77% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| AMGN | JMIA | |
|---|---|---|
Market Cap | $196.12B | $868.21M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $14.60 |
52-Week Low | $271.18 | $4.26 |
Enterprise Value | $241.41B | $815.30M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
JMIA trades at $7.01, up 1.45% today, amid a bearish technical signal and mixed earnings. The company reported Q1 2026 revenue growth of 39% but missed EPS expectations, with a net income margin of -30.79%. Cash flow improved with a net inflow of $21.31M in 2025, and management reaffirmed a 2027 profitability target. The stock shows neutral oscillators but bearish moving averages, with support and resistance clustered around $7.
The outlook hinges on JMIA's path to profitability by 2027, supported by expansion initiatives and partnerships like Starlink. Risks include persistent losses, competitive pressures in African e-commerce, and macroeconomic headwinds. Analyst consensus is strongly bullish with 71% buy ratings, but investors must weigh growth potential against execution risks and current negative returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
